LKQ Corporation reported a net loss of $24 million in Q3 2026, impacted by operational issues in Europe and a $111 million goodwill impairment. Revenue fell 5.1% to $3.3 billion, with Europe facing significant declines due to ERP implementation problems and volume drops. The company appointed Salvatore Abbate as new CEO and suspended its Specialty segment sales process to reassess strategic options. LKQ aims to improve performance and shareholder value under new leadership amid ongoing market challenges.
LKQ Corporation's Q3 2026 results provide context for readers interested in related market activity. As of Oct 29, 2026 17:42 WIB, among 134 priced Consumer Cyclical-sector US stocks tradable on Pluang, 84 rose and 40 fell. Notable movers include Chipotle Mexican Grill (CMG) at USD 31.00 with a 1-day change of +7.71%, MobilEye Global Inc (MBLY) at USD 6.59 down 6.66%, and Rent the Runway Inc (RENT) at USD 2.52 down 6.32%.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
